Jim Weissman

Jim Weissman is the principal of JBW Consulting, focusing on business and corporate development. He also serves as an independent board member for Cerberus Therapeutics and Telesis Bio. Previously, Jim spent over a decade at Dicerna Pharmaceuticals as EVP, COO, and CBO. Dicerna Pharmaceuticals, known for its RNA Interference-based medicines, was acquired by Novo Nordisk for $3.3 billion in late 2021. Jim played a key role in optimizing Dicrna’s GalXC RNAi technology, which supported nearly 20 drug development programs and secured six major corporate collaborations with Alexion, Alnylam, Boehringer Ingelheim, Lilly, Novo Nordisk, and Roche. At the time of the acquisition, the collaborations had yielded over $1B in upfronts, milestones, and related payments. Jim also played a key role in the company’s financings including its successful IPO in 2014.

Prior to his time at Dicerna, Jim was the vice president of business development at MannKind Corporation. He has also held leadership roles in business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, Japan, and various commercial and leadership positions at Pharmacia Biotech in the USA, Sweden, Japan, and the UK. Jim earned a Bachelor of Science degree in chemistry from Bates College.